Pharma Forecast - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharma Forecast
A recent reader poll focused on predictions for the industry's future.


Pharmaceutical Technology
Volume 33, Issue 2, pp. 14


Alexis Pellek
For the second year in a row, PharmTech asked readers in an online poll what area of the pharmaceutical industry they think will experience the most change in the upcoming year. Respondents said that for 2009, regulation policy and enforcement would change the most (25%), followed by manufacturing equipment and processes (23%), and outsourcing and consulting services (17%).

These results differ slightly from what PharmTech readers thought about 2008, when outsourcing (33%) was the number 1 pick, followed by regulation (23%) and information technology (15%). As it turned out, outsourcing was a big topic in 2008. Most notably, there was Baxter's January recall of heparin products and the later discovery that the contaminated active ingredient came from a supplier in China. Later in the year, news arose of the negative impact that last year's economic meltdown had on the third-quarter reports of contract research and manufacturing organizations.

For 2009, readers seem to expect the most news and change in the area of regulation. As the Obama administration works with new staff at FDA, we might see the agency take on topics such as increased oversight of direct-to-consumer advertising, more implementation of quality systems, the development of a regulatory pathway for follow-on biologics, and an emphasis on foreign inspections.

To cast your vote in our biweekly polls and to see the results of past questions, visit our poll archive at http://PharmTech.com/polls.

Alexis Pellek is an assistant editor of Pharmaceutical Technology.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
24%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
15%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here